Kornimate/medical-research-clean huggingface dataset:
simultaneous oct and b-faf in eyes with alteration of the foveal contour

Conditions: Lamellar Macular Hole; Lamellar Macular Pseudohole

Summary: some alterations of the foveal contour do not meet the criteria established for the definition of lamellar macular hole on the basis of optical coherence tomography (oct). however, these alterations may show an appearance, on blue fundus autofluorescence (b-faf) imaging, reminiscent of lamellar macular hole. the aim of the study is to evaluate in detail these alterations recording simultaneously oct and b-faf.

all images will be collected using the heidelberg spectralis system (heidelberg engineering, heidelberg, germany) according to the prespecified imaging protocols. blue-fundus autofluorescence (excitation wavelength at 488 nm and barrier filter at 500 nm) images and sd-oct images will be obtained after pupil dilation. the oct recording protocol will consist of a sequence of 37 horizontal sections, spaced 120-µm apart, covering an area of 20° or 30° horizontally by 15° vertically, and a sequence of 24 radial sections recorded in the high-resolution (hr) mode simultaneously with infrared (ir) images. in addition, simultaneous b-faf/oct images will be acquired (horizontal, and vertical oct sections, centered on the fovea and recorded in the hr mode). the same oct/faf protocol will be used for the study eye and for the fellow eye. for the study eyes that had been examined in the past, the ''follow-up'' function will be used in addition to the prespecified protocol to evaluate if any changes had occurred since the last scan. multiple other morphological characteristics will be analyzed using oct imaging, including the status of the posterior cortex, the presence of operculum, the integrity/disruption of the external limiting membrane (elm), ellipsoid zone (ez), and the central and minimal foveal thickness (cft and mft respectively). the latter will be defined as the thinnest part of the fovea within the foveal pit identified by examining radial scans whereas the former will be measured in relation to the highest point of the foveal bulge. all measurements will be performed using the spectralis built-in manual caliper function at high magnification after adjusting the scale to 1:1 µm except for cft, which will be calculated using the automated ''thickness map'' function of the heidelberg eye explorer.

Eligibility criteria:
inclusion criteria: * alteration of the foveal contour not classifiable as lamellar or pseudo macular hole * focal, well-defined increased autofluorescence signal at the fovea exclusion criteria: * intraretinal cysts not associated with break of the inner retina * juxtafoveal telangiectasia * ring of increased b-faf * vitelliform and pseudovitelliform lesions * history of diabetes, retinal vein occlusion, uveitis, csr, amd or any other retinal -disease potentially associated with intra or subretinal fluid * macular drusen * history of submacular hemorrhage

Keywords: optical coherence tomography blue fundus autofluorescence
a clinical study of mil95 in advanced malignancies.

Conditions: Advanced Malignancies

Summary: this study is composed of two stages: part a initial dose escalation and part b maintenance dose escalation. both parts will adopt the classical 3+3 dose escalation design. the starting dose for phase ia part a is 0.1 mg/kg qw, followed by 3 dose cohorts (0.3mg/kg qw, 0.8mg/kg qw and 1mg/kg qw). duration of dose limiting toxicity (dlt) observation is 14 days. part b will have 5 dose cohorts(3mg/kg qw, 10mg/kg qw, 20mg/kg qw 30mg/kg qw and 45mg/kg qw). dlt observation period is 28 days. the subject number for each cohort in part b will be increased to 6 if the subject number enrolled in each cohort is less than 6.


Eligibility criteria:
inclusion criteria: 1. adult patients, \>=18 years of age; 2. diagnosis of refractory/relapsed lymphomas or solid tumor; 3. eastern cooperative oncology group (ecog) performance status of 0 or 1; 4. life expectancy \>=3 months; 5. sufficient organ and bone marrow function; 6. at least one measurable lesion or evaluable lesion (recist v1.1 or lugano 2014); 7. able and willing to provide written informed consent and to comply with the study protocol. exclusion criteria: 1. prior use of any anti-cancer therapy(including chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc) within 4 weeks of study start; 2. previous exposure to any drug targeting cd47 or sirpα; 3. major surgery within 4 weeks prior to the first administration or expected to undergo major surgery during the study treatment; 4. live attenuated vaccine administrated within 4 weeks before the first administration or during the study period; 5. central nervous system metastasis; 6. history of other primary malignant tumors in 5 years; 7. evidence of significant, uncontrolled concomitant disease; 8. infection with human immunodeficiency virus (hiv), hepatitis b or hepatitis c(including hbsag,hbcab positive with abnormal hbv dna or hcv rna ); 9. active or suspected autoimmune diseases; 10. females of childbearing potential (fcbp) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual contact during the following time periods related to this study: 1) while participating in the study; 2) for at least 12 months after discontinuation of all study treatments; 11. known history of hemolytic anemia; 12. known severe allergic reaction or/and infusion reaction to monoclonal antibody.
effectiveness of a crowdsourced cognitive reappraisal intervention

Conditions: Depression

Summary: this study evaluates a web-based, crowdsourcing platform to promote cognitive reappraisal. half of participants will be granted access to the crowdsourced reappraisal platform. the other half will be provided a web-based expressive writing platform. the investigators hypothesize that the crowdsourcing reappraisal platform will be more effective than the expressive writing platform in promoting positive psychological outcomes.

there are many ways to manage stress and mood, including exercise, diet, and relaxation practices. cognitive-based techniques are also extremely powerful. simply changing how you think about stressful situations can dramatically affect the way you feel. individuals who routinely use strategies like cognitive reappraisal exhibit an enviable affective profile: studies suggest these individuals generally have less stress, lower incidence of depression, and better social functioning than those who rely on less adaptive emotion regulatory techniques. techniques like cognitive reappraisal are also integral to many evidence-based psychotherapeutic traditions, such as cognitive-behavioral therapy and rational-emotive therapy. unfortunately, cognitive techniques can be hard to learn. thinking flexibly about stressful thoughts and situations requires creativity and poise, faculties that often elude us when we need them the most. in this study, the investigators evaluate a web-based technology that uses crowdsourcing and peer-to-peer interactions to help people learn cognitive-based techniques and apply them throughout their daily lives. the goal of the proposed study is to see whether the investigators' technology is more engaging and more effective at reducing depression symptoms than a web-based expressive writing platform. while the investigators are most interested in how this intervention affects depression symptoms, the investigators will also assess other psychological variables and the investigators will open the study to the general population. participation in this study will last three weeks. participants will be randomly assigned to receive either a crowdsourcing reappraisal platform or an expressive writing platform. all study procedures (subject recruitment, baseline and follow-up assessments, interventions) will be conducted online.

Eligibility criteria:
inclusion criteria: * an email account, a desktop computer, and broadband internet access * access to modern web browsers (e.g., chrome, safari, firefox) * native english speaker * 18 to 35 years old exclusion criteria: * planning to be without internet access during the scheduled intervention time
plasma hydrogen sulfide as a biomarker for alzheimer's disease and related dementias

Conditions: Alzheimer Disease; Dementia

Summary: hydrogen sulfide is a signaling molecule that is important for vascular health. because vascular factors such as hypertension and high cholesterol are risk factors for alzheimer's disease and related dementias, we hypothesize that hydrogen sulfide plays an important role in brain health as well. we will compare blood levels of hydrogen sulfide across groups of people with and without dementia. we will also look at the relationship between hydrogen sulfide, cognitive dysfunction and measures of brain microvascular disease examine the contribution of hydrogen sulfide to cognitive decline. our goal is to identify a biomarker of vascular dysfunction in dementia.

we have described hydrogen sulfide (h2s), a signaling molecule important in vascular homeostasis, as a biomarker of cardiovascular disease. there is accumulating evidence that vascular factors such as hypertension, hypercholesterolemia, and type 2 diabetes are associated with increased risk of alzheimer's disease and related dementias (adrd). furthermore, in the brain, h2s acts as a neurotransmitter/second messenger produced following nerve excitation. it also modulates n-methyl-d-aspartate (nmda) receptors during long term potentiation for memory consolidation. three biochemical forms of reactive sulfur pools exist: free h2s, acid-labile (e.g. iron-sulfur clusters) and bound sulfide (e.g. persulfides, polysulfides). we hypothesize that h2s becomes dysregulated in adrd, where vascular and cognitive functions are linked. we will use analytical biochemical methods to measure plasma h2s and its metabolites, and 3t mri to evaluate indicators of microvascular disease in adrd. we will compare h2s levels in people with and without cognitive dysfunction consistent with adrd, and determine the specificity and sensitivity of h2s indistinguishing people with and without cognitive dysfunction. in addition, because previous studies report differences in the incidence and prevalence of adrd by race and sex, we will compare outcomes across these groups as well. finally, we will examine the potentially mediating role of h2s in the relationship between cognitive function and microvascular disease.

Eligibility criteria:
inclusion criteria: * all participants must be aged \>55 years with english as the 1⁰ language, with stable permitted medications for \<4 weeks, geriatric depression scale score \<6, visual and auditory acuity adequate to perform tests, and history of education excluding developmental cognitive abnormalities. exclusion criteria: * exclusion criteria are history of significant neurologic disease or mental illness, unstable medical conditions that could interfere with completion of study, substance abuse within 2 years, contraindications to mri, abnormal findings on mri, history of chronic kidney disease, and investigational agents within 1 month of participation.

Keywords: biomarker vascular disease sex differences race differences
a clinical study evaluating the safety and efficacy of idp-110 in patients with acne vulgaris

Conditions: Acne Vulgaris

Summary: the purpose of this study is to assess the effectiveness of idp-110 in treating patients with acne vulgaris.


Eligibility criteria:
inclusion criteria: * presence of inflammatory and non-inflammatory lesions exclusion criteria: * dermatological conditions of the face other than acne that could interfere with clinical evaluations * female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study
effect of oxytocin on masked facial expressions: an fmri study

Conditions: Facial Expressions

Summary: the purpose is to test whether oxytocin has an effect on masked facial expressions

the neuropeptide oxytocin (oxt) has been shown to modulate several aspects of human social cognition. although the exact mechanisms behind these effects remain unclear, recent research suggests that oxt modulates the perception of cues that are important for interpersonal processing, particularly emotional facial expressions. using a backward masking procedure and functional magnetic resonance imaging, we investigated the modulatory effects of intranasal oxt on the processing of sub-liminally presented emotional faces. in a double-blind placebo-controlled between-subject pharmaco-fmri experiment healthy volunteers received either 24iu of intranasal oxytocin or placebo 45mins before they were presented emotional (happy, angry, fearful, sad, disgusting) faces and mirror-reversed neutral faces masked by neutral faces of the same individual. to ensure attentional processing of the faces subjects were required to perform a simple gender decision task in the scanner and a recognition memory task afterwards. all subjects were additionally assessed for their state and trait anxiety and depression as well as empathy. for the analysis, we will use matlab, spm and spss to conduct structural roi analysis and two sample t test.

Eligibility criteria:
inclusion criteria: * healthy subjects, no smoke or drink alcohol, coffee or other stimulants during the day before experiment. exclusion criteria: * history of head injury; pregnancy; uterine cavity operations were took within one year; medical or psychiatric illness; rhinitis in case they may not fully absorb the spray.

Keywords: treatment mask face exoressions genier
pelvic floor contraction in different positions among women with and without stress urinary incontinence

Conditions: Urinary Stress Incontinence

Summary: examination of pelvic floor contraction in different positions among women with and without stress urinary incontinence (sui) will be conducted via diagnostic ultrasound. this will enable clinicians and researchers to establish an appropriate protocol for pelvic floor muscle examination and treatment.

the main goal of this study is to compare the ability of the pelvic floor muscles to contract in different positions among women suffering from sui to healthy women. secondary objectives: is to compare subjective reports of the difficulty to contract the pelvic floor muscles between the two groups, and to examine the connection between the severity of urinary leakage and the ability to contract pelvic floor muscles. the study will include 50 female participants in the ages of 18-45. research group will include 25 participants suffering from sui in accordance with the international consultation on incontinence questionnaire short form (iciq-sf) and 25 healthy participants (grade 0 on the iciq-sf questionnaire). the examination will be performed with an abdominal ultrasound device in supine, sitting, standing and squatting. the height of the bladder base will be measured during rest period and maximal contraction. the extent and direction of bladder base movement would indicate the quality of pelvic floor performance. next, the length of contraction time will be measured. the participant would hold the maximal contraction as long as possible in order to examine muscular endurance. rest will be given between tests. after finishing the tests in all four postures, the participants will be questioned about the degree of difficulty contracting the pelvic floor. significance of the study: the importance of the research is about granting the clinicians and researchers additional tools in order to help establishing a protocol for pelvic floor muscle activity examination and treatment.

Eligibility criteria:
inclusion criteria (general): * willing to participate in the study * being able to squat for over 10 seconds. * inclusion for study group - participants suffering from sui that received a grade\>0 in sections 3+4 (how frequent does urinary leakage appear, the amount of urine leakage and does the participant use pads for leakage absorption) and a grade\>0 in section 5 (how much does sui interrupt the participant's daily life) in the international consultation on incontinence questionnaire short form (iciq-sf). * inclusion for control group - healthy participants (grade 0 in the iciq- sf questionnaire). exclusion criteria: * other types of urinary leakage * receiving pelvic floor treatments in the past or present * active urinary or vaginal infections * neurological diseases * urologic, gynecologic or abdominal surgery * pelvic organ prolapse * pregnancy * chronic cough * constipation * unbalanced diabetes and the use of medication that affects urination
effect of paravertebral muscle fat infiltration on rocuronium use in lumbar surgery

Conditions: Spinal Stenosis Lumbar

Summary: to investigate the effect of different degrees of fat infiltration on rocuronium use in lumbar surgery was monitored by trapezius muscle relaxation.

select the patients who will receive posterior lumbar surgery in the second hospital of shanxi medical university. according to the classification criteria of fat infiltration, it will be divided into three groups: mild, moderate and severe. this study will pump and titrate rocuronium bromide under the monitoring of muscle relaxation during the operation, record the dosage of rocuronium bromide and the duration of pump injection, and evaluate its clinical effect. postoperative results include the use and clinical effect of rocuronium, which will be counted after the trial.

Eligibility criteria:
inclusion criteria: age: 18-65; asa grade i-ii; no significant cardiopulmonary disease; no history of surgery in the corresponding surgical area; no coagulopathy. exclusion criteria: refusal to participate by the present experimenter; those with severe cardio-cerebrovascular disease, severe hepatic and renal dysfunction; taking medications affecting the neuromuscular junction; area of monitoring site for skin breakers; patients with intraoperative bleeding, anaphylactic shock, or other serious complications; patients requiring intraoperative neurophysiological monitoring (including sensory, motor evoked potentials).
a randomized, comparative, prospective study of daily trimethoprim / sulfamethoxazole (tms) and thrice-weekly tms for prophylaxis against pcp in hiv-infected patients

Conditions: Pneumonia, Pneumocystis Carinii; HIV Infections

Summary: to compare the safety and efficacy of two dosage regimens (daily and thrice-weekly) of sulfamethoxazole/trimethoprim (smx/tmp; tms) in the prevention of pneumocystis carinii pneumonia (pcp) in high-risk hiv-infected patients. previous tests have shown that smx/tmp given daily is effective in preventing recurrence of pcp and may be effective in preventing pcp in patients who have never developed it. because smx/tmp can cause side effects, this study will attempt to determine the safest and most effective dose of this combination.

previous tests have shown that smx/tmp given daily is effective in preventing recurrence of pcp and may be effective in preventing pcp in patients who have never developed it. because smx/tmp can cause side effects, this study will attempt to determine the safest and most effective dose of this combination. patients receive smx/tmp orally on a daily or thrice-weekly basis. patients are clinically evaluated every 4 months. patients on daily smx/tmp who develop a drug-related toxicity may be switched to thrice-weekly smx/tmp. duration of follow-up is 12 months.

Eligibility criteria:
inclusion criteria patients must have: * hiv infection. * cd4 count \<= 200 cells/mm3 or a history of prior pcp. * no active pneumocystosis. patients or their guardians must sign informed consent. pregnant patients are eligible at the clinician's discretion. patients who do not meet required laboratory values may be eligible at the discretion of the clinician. exclusion criteria co-existing condition: patients with the following symptoms and conditions are excluded: * known treatment-limiting reaction to sulfonamides or trimethoprim. concurrent medication: excluded: * other pcp prophylaxis or medication with anti-pcp activity.

Keywords: trimethoprim-sulfamethoxazole combination pneumonia, pneumocystis carinii acquired immunodeficiency syndrome aids-related complex sulfamethoxazole-trimethoprim
keratinocyte growth factor to prevent acute gvhd

Conditions: Graft-vs-Host Disease

Summary: this is a study to determine the safety and efficacy of keratinocyte growth factor (kgf) to prevent acute graft-versus-host disease (gvhd) in patients undergoing allogeneic bone marrow (bm) or peripheral blood progenitor cell (pbpc) transplantation.

gvhd remains the major complication of allogeneic bm transplantation and is initiated during the conditioning of the recipient for transplant when the host tissues are damaged. research has demonstrated that the gastrointestinal (gi) tract is a critical organ in gvhd pathophysiology. agents that protect the gi tract may provide prophylaxis against the cytokine cascade and can lead to a reduced incidence and severity of gvhd. kgf is a protein that stimulates the growth of epithelial cells including those of the gi tract. kgf can protect the gi tract, prevent gvhd, and preserve donor t-cell function. patients will receive standard gvhd prophylaxis in addition to the study drug. overall gvhd will be graded weekly during the first 2 months after transplant, then every other week to day 100. response to therapy will be measured through the use of severity indices, physical exam, and laboratory serum values.

Eligibility criteria:
inclusion criteria: * diagnosis of a hematological malignancy, including myelodysplastic syndromes. * eligible for cyclophosphamide and total body irradiation conditioning therapy or busulphan and cyclophosphamide conditioning therapy. * must have a 6/6 human leukocyte antigens (hla)-matched family member donor. * women must be post-menopausal, sterile, or using effective contraception for 1 month before, during, and for 2 months after study. * eastern cooperative oncology group (ecog) performance status 0-2. exclusion criteria: * t-cell depletion for gvhd prophylaxis. * active hepatitis. * pre-existent inflammatory bowel disease requiring active therapy. * active uncontrolled infection. * prior bone marrow or peripheral blood stem cell (pbsc) transplantation. * documented hypersensitivity to rhukgf. * prior enrollment to a study of rhukgf. * hiv-positive. * pregnant or nursing. * active chronic skin disease requiring therapy.

Keywords: keratinocyte growth factor bone marrow transplantation hematopoietic stem cell transplantation hla antigens transplantation, homologous recombinant proteins